摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-((S)-2-(4,4-Pentamethylene-3-(4-(3-(2-methylphenyl)ureido)benzyl)-2,5-dioxoimidazolidin-1-yl)-2-(2-methylpropyl)acetylamino)-3-methylpropionamide | 306768-72-9

中文名称
——
中文别名
——
英文名称
(R)-3-((S)-2-(4,4-Pentamethylene-3-(4-(3-(2-methylphenyl)ureido)benzyl)-2,5-dioxoimidazolidin-1-yl)-2-(2-methylpropyl)acetylamino)-3-methylpropionamide
英文别名
(2S)-N-[(2R)-4-amino-4-oxobutan-2-yl]-4-methyl-2-[1-[[4-[(2-methylphenyl)carbamoylamino]phenyl]methyl]-2,4-dioxo-1,3-diazaspiro[4.5]decan-3-yl]pentanamide
(R)-3-((S)-2-(4,4-Pentamethylene-3-(4-(3-(2-methylphenyl)ureido)benzyl)-2,5-dioxoimidazolidin-1-yl)-2-(2-methylpropyl)acetylamino)-3-methylpropionamide化学式
CAS
306768-72-9
化学式
C33H44N6O5
mdl
——
分子量
604.75
InChiKey
OXBHPQYIZMLABX-KCWPFWIISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    44
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    154
  • 氢给体数:
    4
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM
    申请人:Aventis Pharma Deutschland GmbH
    公开号:EP1183241A1
    公开(公告)日:2002-03-06
  • JP2002544261A
    申请人:——
    公开号:JP2002544261A
    公开(公告)日:2002-12-24
  • スピロイミダゾリジン誘導体、それらの製造、それらの使用およびそれらを含有する医薬製剤
    申请人:アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
    公开号:JP4686029B2
    公开(公告)日:2002-12-24
  • US6399643B1
    申请人:——
    公开号:US6399643B1
    公开(公告)日:2002-06-04
  • [EN] SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM<br/>[FR] DERIVES DE SPIROIMIDAZOLIDINE, PREPARATION ET UTILISATION DE CES DERIVES ET PREPARATION PHARMACEUTIQUES A BASE DE CES DERIVES.
    申请人:AVENTIS PHARMA GMBH
    公开号:WO2000069831A1
    公开(公告)日:2000-11-23
    The present invention relates to spiroimidazolidine derivatives of formula (I) in which E, V, W, X, R?1 and R2¿ have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of formula (I) are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of formula (I), their use and pharmaceutical preparations which contain compounds of formula (I).
查看更多